New drug hope for rare nerve cancer: tazemetostat under study
NCT ID NCT04917042
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests the drug tazemetostat in 10 people with recurrent, treatment-resistant, or metastatic malignant peripheral nerve sheath tumors (MPNST), a rare and aggressive cancer. Participants take tazemetostat pills twice daily for up to 2 years. The main goal is to see if the drug can shrink tumors or stop them from growing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tazemetostat (TAZVERIK)
- What this could lead to
- If it works, this could point toward a new treatment option for people with advanced MPNST, a rare and aggressive cancer.
- What could go wrong
- This is a small, early-phase trial with only 10 participants, so results may not apply broadly. The drug may not shrink tumors or improve survival, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT PERIPHERAL NERVE SHEATH TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Florida
Gainesville, Florida, 32608, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New imaging agent aims to light up hidden tumors
- New drug cocktail shows promise for rare sarcomas
- New hope for rare cancers: experimental drug ADCT-701 enters human trials
- Experimental combo aims to boost immune attack on sarcoma before surgery
- New drug combo shows promise for Hard-to-Treat sarcomas
- Blood test could spot rare nerve tumors years earlier in NF1 patients